[1]
Dawson, M.A.; Kouzarides, T. Cancer epigenetics: from mechanism to therapy. Cell, 2012, 150(1), 12-27. [http://dx.doi.org/10.1016/j.cell.2012.06.013]. [PMID: 22770212].
[2]
Kouzarides, T. Chromatin modifications and their function. Cell, 2007, 128(4), 693-705. [http://dx.doi.org/10.1016/j.cell.2007.02.005]. [PMID: 17320507].
[3]
Strahl, B.D.; Allis, C.D. The language of covalent histone modifications. Nature, 2000, 403(6765), 41-45. [http://dx.doi.org/10.1038/47412]. [PMID: 10638745].
[4]
Bannister, A.J.; Kouzarides, T. Histone methylation: recognizing the methyl mark. Methods Enzymol., 2004, 376, 269-288. [http://dx.doi.org/10.1016/S0076-6879(03)76018-2]. [PMID: 14975312].
[5]
Pogo, B.G.; Allfrey, V.G.; Mirsky, A.E. RNA synthesis and histone acetylation during the course of gene activation in lymphocytes. Proc. Natl. Acad. Sci. USA, 1966, 55(4), 805-812. [http://dx.doi.org/10.1073/pnas.55.4.805]. [PMID: 5219687].
[6]
Fraga, M.F.; Ballestar, E.; Villar-Garea, A.; Boix-Chornet, M.; Espada, J.; Schotta, G.; Bonaldi, T.; Haydon, C.; Ropero, S.; Petrie, K.; Iyer, N.G.; Pérez-Rosado, A.; Calvo, E.; Lopez, J.A.; Cano, A.; Calasanz, M.J.; Colomer, D.; Piris, M.A.; Ahn, N.; Imhof, A.; Caldas, C.; Jenuwein, T.; Esteller, M. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet., 2005, 37(4), 391-400. [http://dx.doi.org/10.1038/ng1531]. [PMID: 15765097].
[7]
Keohane, A.M.; O’neill, L.P.; Belyaev, N.D.; Lavender, J.S.; Turner, B.M. X-Inactivation and histone H4 acetylation in embryonic stem cells. Dev. Biol., 1996, 180(2), 618-630. [http://dx.doi.org/10.1006/dbio.1996.0333]. [PMID: 8954732].
[8]
Zhai, L.; Joo, H.Y.; Wang, H. In vitro and in vivo assays for studying histone ubiquitination and deubiquitination. Methods Mol. Biol., 2009, 523, 295-309. [http://dx.doi.org/10.1007/978-1-59745-190-1_20]. [PMID: 19381930].
[9]
Yang, X.J.; Grégoire, S. Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol. Cell. Biol., 2005, 25(8), 2873-2884. [http://dx.doi.org/10.1128/MCB.25.8.2873-2884.2005]. [PMID: 15798178].
[10]
Lunyak, V.V.; Burgess, R.; Prefontaine, G.G.; Nelson, C.; Sze, S.H.; Chenoweth, J.; Schwartz, P.; Pevzner, P.A.; Glass, C.; Mandel, G.; Rosenfeld, M.G. Corepressor-dependent silencing of chromosomal regions encoding neuronal genes. Science, 2002, 298(5599), 1747-1752. [http://dx.doi.org/10.1126/science.1076469]. [PMID: 12399542].
[11]
Tong, J.J.; Liu, J.; Bertos, N.R.; Yang, X.J. Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain. Nucleic Acids Res., 2002, 30(5), 1114-1123. [http://dx.doi.org/10.1093/nar/30.5.1114]. [PMID: 11861901].
[12]
Guardiola, A.R.; Yao, T.P. Molecular cloning and characterization of a novel histone deacetylase HDAC10. J. Biol. Chem., 2002, 277(5), 3350-3356. [http://dx.doi.org/10.1074/jbc.M109861200]. [PMID: 11726666].
[13]
Hubbert, C.; Guardiola, A.; Shao, R.; Kawaguchi, Y.; Ito, A.; Nixon, A.; Yoshida, M.; Wang, X.F.; Yao, T.P. HDAC6 is a microtubule-associated deacetylase. Nature, 2002, 417(6887), 455-458. [http://dx.doi.org/10.1038/417455a]. [PMID: 12024216].
[14]
Yoshida, M.; Kijima, M.; Akita, M.; Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem., 1990, 265(28), 17174-17179. [PMID: 2211619].
[15]
Gao, L.; Cueto, M.A.; Asselbergs, F.; Atadja, P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem., 2002, 277(28), 25748-25755. [http://dx.doi.org/10.1074/jbc.M111871200]. [PMID: 11948178].
[16]
Finkel, T.; Deng, C.X.; Mostoslavsky, R. Recent progress in the biology and physiology of sirtuins. Nature, 2009, 460(7255), 587-591. [http://dx.doi.org/10.1038/nature08197]. [PMID: 19641587].
[17]
Kao, H.Y.; Lee, C.H.; Komarov, A.; Han, C.C.; Evans, R.M. Isolation and characterization of mammalian HDAC10, a novel histone deacetylase. J. Biol. Chem., 2002, 277(1), 187-193. [http://dx.doi.org/10.1074/jbc.M108931200]. [PMID: 11677242].
[18]
Grozinger, C.M.; Hassig, C.A.; Schreiber, S.L. Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc. Natl. Acad. Sci. USA, 1999, 96(9), 4868-4873. [http://dx.doi.org/10.1073/pnas.96.9.4868]. [PMID: 10220385].
[19]
Vanommeslaeghe, K.; Van Alsenoy, C.; De Proft, F.; Martins, J.C.; Tourwé, D.; Geerlings, P. Ab initio study of the binding of Trichostatin A (TSA) in the active site of histone deacetylase like protein (HDLP). Org. Biomol. Chem., 2003, 1(16), 2951-2957. [http://dx.doi.org/10.1039/B304707E]. [PMID: 12968347].
[20]
Grant, S.; Easley, C.; Kirkpatrick, P. Vorinostat. Nat. Rev. Drug Discov., 2007, 6(1), 21-22. [http://dx.doi.org/10.1038/nrd2227]. [PMID: 17269160].
[21]
Warrel, R.P.H.L-Z.; Richon, V.; Calleja, E.; Pandolfi, P.P. Therapeutic targeting of transcription in acute promyelocitic leukemia by use of an inhibitor of histone deacetylases. J. Natl. Cancer Inst., 1998, 90, 1621-1625. [http://dx.doi.org/10.1093/jnci/90.21.1621]. [PMID: 9811311].
[22]
Senese, S.; Zaragoza, K.; Minardi, S.; Muradore, I.; Ronzoni, S.; Passafaro, A.; Bernard, L.; Draetta, G.F.; Alcalay, M.; Seiser, C.; Chiocca, S. Role for histone deacetylase 1 in human tumor cell proliferation. Mol. Cell. Biol., 2007, 27(13), 4784-4795. [http://dx.doi.org/10.1128/MCB.00494-07]. [PMID: 17470557].
[23]
Sasaki, H.; Moriyama, S.; Nakashima, Y.; Kobayashi, Y.; Kiriyama, M.; Fukai, I.; Yamakawa, Y.; Fujii, Y. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer, 2004, 46(2), 171-178. [http://dx.doi.org/10.1016/j.lungcan.2004.03.021]. [PMID: 15474665].
[24]
Huang, B.H.; Laban, M.; Leung, C.H.; Lee, L.; Lee, C.K.; Salto-Tellez, M.; Raju, G.C.; Hooi, S.C. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ., 2005, 12(4), 395-404. [http://dx.doi.org/10.1038/sj.cdd.4401567]. [PMID: 15665816].
[25]
Qian, D.Z.; Kachhap, S.K.; Collis, S.J.; Verheul, H.M.; Carducci, M.A.; Atadja, P.; Pili, R. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res., 2006, 66(17), 8814-8821. [http://dx.doi.org/10.1158/0008-5472.CAN-05-4598]. [PMID: 16951198].
[26]
Chauchereau, A.; Mathieu, M.; de Saintignon, J.; Ferreira, R.; Pritchard, L.L.; Mishal, Z.; Dejean, A.; Harel-Bellan, A. HDAC4 mediates transcriptional repression by the acute promyelocytic leukaemia-associated protein PLZF. Oncogene, 2004, 23(54), 8777-8784. [http://dx.doi.org/10.1038/sj.onc.1208128]. [PMID: 15467736].
[27]
Grunstein, M. Histone acetylation in chromatin structure and transcription. Nature, 1997, 389(6649), 349-352. [http://dx.doi.org/10.1038/38664]. [PMID: 9311776].
[28]
Hassig, C.A.; Schreiber, S.L. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr. Opin. Chem. Biol., 1997, 1(3), 300-308. [http://dx.doi.org/10.1016/S1367-5931(97)80066-X]. [PMID: 9667866].
[29]
Baek, Y.S.; Haas, S.; Hackstein, H.; Bein, G.; Hernandez-Santana, M.; Lehrach, H.; Sauer, S.; Seitz, H. Identification of novel transcriptional regulators involved in macrophage differentiation and activation in U937 cells. BMC Immunol., 2009, 10, 18. [http://dx.doi.org/10.1186/1471-2172-10-18]. [PMID: 19341462].
[30]
Ueki, N.; Zhang, L.; Hayman, M.J. Ski can negatively regulates macrophage differentiation through its interaction with PU.1. Oncogene, 2008, 27(3), 300-307. [http://dx.doi.org/10.1038/sj.onc.1210654]. [PMID: 17621263].
[31]
Into, T.; Inomata, M.; Niida, S.; Murakami, Y.; Shibata, K. Regulation of MyD88 aggregation and the MyD88-dependent signaling pathway by sequestosome 1 and histone deacetylase 6. J. Biol. Chem., 2010, 285(46), 35759-35769. [http://dx.doi.org/10.1074/jbc.M110.126904]. [PMID: 20837465].
[32]
Chen, Lf. Fischle, W.; Verdin, E.; Greene, W.C. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science, 2001, 293(5535), 1653-1657. [http://dx.doi.org/10.1126/science.1062374]. [PMID: 11533489].
[33]
Elsharkawy, A.M.; Oakley, F.; Lin, F.; Packham, G.; Mann, D.A.; Mann, J. The NF-kappaB p50:p50:HDAC-1 repressor complex orchestrates transcriptional inhibition of multiple pro-inflammatory genes. J. Hepatol., 2010, 53(3), 519-527. [http://dx.doi.org/10.1016/j.jhep.2010.03.025]. [PMID: 20579762].
[34]
Choi, Y.S.; Jeong, S. PI3-kinase and PDK-1 regulate HDAC1-mediated transcriptional repression of transcription factor NF-kappaB. Mol. Cells, 2005, 20(2), 241-246. [PMID: 16267399].
[35]
Ashburner, B.P.; Westerheide, S.D.; Baldwin, A.S., Jr The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell. Biol., 2001, 21(20), 7065-7077. [http://dx.doi.org/10.1128/MCB.21.20.7065-7077.2001]. [PMID: 11564889].
[36]
Pakala, S.B.; Bui-Nguyen, T.M.; Reddy, S.D.; Li, D.Q.; Peng, S.; Rayala, S.K.; Behringer, R.R.; Kumar, R. Regulation of NF-kappaB circuitry by a component of the nucleosome remodeling and deacetylase complex controls inflammatory response homeostasis. J. Biol. Chem., 2010, 285(31), 23590-23597. [http://dx.doi.org/10.1074/jbc.M110.139469]. [PMID: 20519513].
[37]
Shim, J.Y.; Bertalovitz, A.C.; Kendall, D.A. Identification of essential cannabinoid-binding domains: structural insights into early dynamic events in receptor activation. J. Biol. Chem., 2011, 286(38), 33422-33435. [http://dx.doi.org/10.1074/jbc.M111.261651]. [PMID: 21795705].
[38]
Kim, S.H.; Jeong, J.W.; Park, J.A.; Lee, J.W.; Seo, J.H.; Jung, B.K.; Bae, M.K.; Kim, K.W. Regulation of the HIF-1alpha stability by histone deacetylases. Oncol. Rep., 2007, 17(3), 647-651. [PMID: 17273746].
[39]
Cao, W.; Bao, C.; Padalko, E.; Lowenstein, C.J. Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signaling. J. Exp. Med., 2008, 205(6), 1491-1503. [http://dx.doi.org/10.1084/jem.20071728]. [PMID: 18504304].
[40]
Nusinzon, I.; Horvath, C.M. Positive and negative regulation of the innate antiviral response and beta interferon gene expression by deacetylation. Mol. Cell. Biol., 2006, 26(8), 3106-3113. [http://dx.doi.org/10.1128/MCB.26.8.3106-3113.2006]. [PMID: 16581785].
[41]
Nencioni, A.; Beck, J.; Werth, D.; Grünebach, F.; Patrone, F.; Ballestrero, A.; Brossart, P. Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin. Cancer Res., 2007, 13(13), 3933-3941. [http://dx.doi.org/10.1158/1078-0432.CCR-06-2903]. [PMID: 17606727].
[42]
Salvi, V.; Bosisio, D.; Mitola, S.; Andreoli, L.; Tincani, A.; Sozzani, S. Trichostatin A blocks type I interferon production by activated plasmacytoid dendritic cells. Immunobiology, 2010, 215(9-10), 756-761. [http://dx.doi.org/10.1016/j.imbio.2010.05.023]. [PMID: 20573419].
[43]
Bode, K.A.; Schroder, K.; Hume, D.A.; Ravasi, T.; Heeg, K.; Sweet, M.J.; Dalpke, A.H. Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology, 2007, 122(4), 596-606. [http://dx.doi.org/10.1111/j.1365-2567.2007.02678.x]. [PMID: 17635610].
[44]
Murphy, P.J.; Morishima, Y.; Kovacs, J.J.; Yao, T.P.; Pratt, W.B. Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone. J. Biol. Chem., 2005, 280(40), 33792-33799. [http://dx.doi.org/10.1074/jbc.M506997200]. [PMID: 16087666].
[45]
Tang, X.; Gao, J.S.; Guan, Y.J.; McLane, K.E.; Yuan, Z.L.; Ramratnam, B.; Chin, Y.E. Acetylation-dependent signal transduction for type I interferon receptor. Cell, 2007, 131(1), 93-105. [http://dx.doi.org/10.1016/j.cell.2007.07.034]. [PMID: 17923090].
[46]
Zupkovitz, G.; Tischler, J.; Posch, M.; Sadzak, I.; Ramsauer, K.; Egger, G.; Grausenburger, R.; Schweifer, N.; Chiocca, S.; Decker, T.; Seiser, C. Negative and positive regulation of gene expression by mouse histone deacetylase 1. Mol. Cell. Biol., 2006, 26(21), 7913-7928. [http://dx.doi.org/10.1128/MCB.01220-06]. [PMID: 16940178].
[47]
Klampfer, L.; Huang, J.; Swaby, L.A.; Augenlicht, L. Requirement of histone deacetylase activity for signaling by STAT1. J. Biol. Chem., 2004, 279(29), 30358-30368. [http://dx.doi.org/10.1074/jbc.M401359200]. [PMID: 15123634].
[48]
Antunes, F.; Marg, A.; Vinkemeier, U. STAT1 signaling is not regulated by a phosphorylation-acetylation switch. Mol. Cell. Biol., 2011, 31(14), 3029-3037. [http://dx.doi.org/10.1128/MCB.05300-11]. [PMID: 21576370].
[49]
Xu, D.; Holko, M.; Sadler, A.J.; Scott, B.; Higashiyama, S.; Berkofsky-Fessler, W.; McConnell, M.J.; Pandolfi, P.P.; Licht, J.D.; Williams, B.R. Promyelocytic leukemia zinc finger protein regulates interferon-mediated innate immunity. Immunity, 2009, 30(6), 802-816. [http://dx.doi.org/10.1016/j.immuni.2009.04.013]. [PMID: 19523849].
[50]
Villagra, A.; Cheng, F.; Wang, H.W.; Suarez, I.; Glozak, M.; Maurin, M.; Nguyen, D.; Wright, K.L.; Atadja, P.W.; Bhalla, K.; Pinilla-Ibarz, J.; Seto, E.; Sotomayor, E.M. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat. Immunol., 2009, 10(1), 92-100. [http://dx.doi.org/10.1038/ni.1673]. [PMID: 19011628].
[51]
Zika, E.; Greer, S.F.; Zhu, X.S.; Ting, J.P. Histone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation. Mol. Cell. Biol., 2003, 23(9), 3091-3102. [http://dx.doi.org/10.1128/MCB.23.9.3091-3102.2003]. [PMID: 12697811].
[52]
Kong, X.; Fang, M.; Li, P.; Fang, F.; Xu, Y. HDAC2 deacetylates class II transactivator and suppresses its activity in macrophages and smooth muscle cells. J. Mol. Cell. Cardiol., 2009, 46(3), 292-299. [http://dx.doi.org/10.1016/j.yjmcc.2008.10.023]. [PMID: 19041327].
[53]
Aung, H.T.; Schroder, K.; Himes, S.R.; Brion, K.; van Zuylen, W.; Trieu, A.; Suzuki, H.; Hayashizaki, Y.; Hume, D.A.; Sweet, M.J.; Ravasi, T. LPS regulates proinflammatory gene expression in macrophages by altering histone deacetylase expression. FASEB J., 2006, 20(9), 1315-1327. [http://dx.doi.org/10.1096/fj.05-5360com]. [PMID: 16816106].
[54]
Gilchrist, M.; Thorsson, V.; Li, B.; Rust, A.G.; Korb, M.; Roach, J.C.; Kennedy, K.; Hai, T.; Bolouri, H.; Aderem, A. Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature, 2006, 441(7090), 173-178. [http://dx.doi.org/10.1038/nature04768]. [PMID: 16688168].
[55]
Foster, S.L.; Hargreaves, D.C.; Medzhitov, R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature, 2007, 447(7147), 972-978. [http://dx.doi.org/10.1038/nature05836]. [PMID: 17538624].
[56]
Micelli, C.; Rastelli, G. Histone deacetylases: structural determinants of inhibitor selectivity. Drug Discov. Today, 2015, 20(6), 718-735. [http://dx.doi.org/10.1016/j.drudis.2015.01.007]. [PMID: 25687212].
[57]
Estiu, G.; Greenberg, E.; Harrison, C.B.; Kwiatkowski, N.P.; Mazitschek, R.; Bradner, J.E.; Wiest, O. Structural origin of selectivity in class II-selective histone deacetylase inhibitors. J. Med. Chem., 2008, 51(10), 2898-2906. [http://dx.doi.org/10.1021/jm7015254]. [PMID: 18412327].
[58]
Roche, J.; Bertrand, P. Inside HDACs with more selective HDAC inhibitors. Eur. J. Med. Chem., 2016, 121, 451-483. [http://dx.doi.org/10.1016/j.ejmech.2016.05.047]. [PMID: 27318122].
[59]
Furumai, R.; Matsuyama, A.; Kobashi, N.; Lee, K.H.; Nishiyama, M.; Nakajima, H.; Tanaka, A.; Komatsu, Y.; Nishino, N.; Yoshida, M.; Horinouchi, S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res., 2002, 62(17), 4916-4921. [PMID: 12208741].
[60]
Riggs, M.G.; Whittaker, R.G.; Neumann, J.R.; Ingram, V.M. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature, 1977, 268(5619), 462-464. [http://dx.doi.org/10.1038/268462a0]. [PMID: 268489].
[61]
Hu, E.; Dul, E.; Sung, C.M.; Chen, Z.; Kirkpatrick, R.; Zhang, G.F.; Johanson, K.; Liu, R.; Lago, A.; Hofmann, G.; Macarron, R.; de los Frailes, M.; Perez, P.; Krawiec, J.; Winkler, J.; Jaye, M. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther., 2003, 307(2), 720-728. [http://dx.doi.org/10.1124/jpet.103.055541]. [PMID: 12975486].
[62]
Halili, M.A.; Andrews, M.R.; Sweet, M.J.; Fairlie, D.P. Histone deacetylase inhibitors in inflammatory disease. Curr. Top. Med. Chem., 2009, 9(3), 309-319. [http://dx.doi.org/10.2174/156802609788085250]. [PMID: 19355993].
[63]
Kazantsev, A.G.; Thompson, L.M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov., 2008, 7(10), 854-868. [http://dx.doi.org/10.1038/nrd2681]. [PMID: 18827828].
[64]
Tan, J.; Cang, S.; Ma, Y.; Petrillo, R.L.; Liu, D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol., 2010, 3, 5. [http://dx.doi.org/10.1186/1756-8722-3-5]. [PMID: 20132536].
[65]
Wagner, J.M.; Hackanson, B.; Lübbert, M.; Jung, M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin. Epigenetics, 2010, 1(3-4), 117-136. [http://dx.doi.org/10.1007/s13148-010-0012-4]. [PMID: 21258646].
[67]
Meng, J.; Li, Y.; Camarillo, C.; Yao, Y.; Zhang, Y.; Xu, C.; Jiang, L. The anti-tumor histone deacetylase inhibitor SAHA and the natural flavonoid curcumin exhibit synergistic neuroprotection against amyloid-beta toxicity. PLoS One, 2014, 9(1)e85570 [http://dx.doi.org/10.1371/journal.pone.0085570]. [PMID: 24409332].
[68]
Leng, Y.; Marinova, Z.; Reis-Fernandes, M.A.; Nau, H.; Chuang, D.M. Potent neuroprotective effects of novel structural derivatives of valproic acid: potential roles of HDAC inhibition and HSP70 induction. Neurosci. Lett., 2010, 476(3), 127-132. [http://dx.doi.org/10.1016/j.neulet.2010.04.013]. [PMID: 20394799].
[69]
Nau, H.; Wittfoht, W.; Schäfer, H.; Jakobs, C.; Rating, D.; Helge, H. Valproic acid and several metabolites: quantitative determination in serum, urine, breast milk and tissues by gas chromatography-mass spectrometry using selected ion monitoring. J. Chromatogr. A, 1981, 226(1), 69-78. [http://dx.doi.org/10.1016/S0378-4347(00)84207-3]. [PMID: 6798056].
[70]
Cheng, K.; Masters, S.; Stephenson, T.; Cooke, R.; Ferner, R.; Ashworth, M.; Nunn, A.J. Identification of suspected fatal adverse drug reactions by paediatricians: a UK surveillance study. Arch. Dis. Child., 2008, 93(7), 609-611. [http://dx.doi.org/10.1136/adc.2006.107789]. [PMID: 17588966].
[71]
Phiel, C.J.; Zhang, F.; Huang, E.Y.; Guenther, M.G.; Lazar, M.A.; Klein, P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem., 2001, 276(39), 36734-36741. [http://dx.doi.org/10.1074/jbc.M101287200]. [PMID: 11473107].
[72]
Göttlicher, M.; Minucci, S.; Zhu, P.; Krämer, O.H.; Schimpf, A.; Giavara, S.; Sleeman, J.P.; Lo Coco, F.; Nervi, C.; Pelicci, P.G.; Heinzel, T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J., 2001, 20(24), 6969-6978. [http://dx.doi.org/10.1093/emboj/20.24.6969]. [PMID: 11742974].
[73]
Lu, Q.; Wang, D.S.; Chen, C.S.; Hu, Y.D.; Chen, C.S. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J. Med. Chem., 2005, 48(17), 5530-5535. [http://dx.doi.org/10.1021/jm0503749]. [PMID: 16107152].
[74]
Shirakawa, K.; Chavez, L.; Hakre, S.; Calvanese, V.; Verdin, E. Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol., 2013, 21(6), 277-285. [http://dx.doi.org/10.1016/j.tim.2013.02.005]. [PMID: 23517573].
[75]
Schiattarella, G.G.; Sannino, A.; Toscano, E.; Cattaneo, F.; Trimarco, B.; Esposito, G.; Perrino, C. Cardiovascular effects of histone deacetylase inhibitors epigenetic therapies: Systematic review of 62 studies and new hypotheses for future research. Int. J. Cardiol., 2016, 219, 396-403. [http://dx.doi.org/10.1016/j.ijcard.2016.06.012]. [PMID: 27362830].
[76]
Jønsson, K.L.; Tolstrup, M.; Vad-Nielsen, J.; Kjær, K.; Laustsen, A.; Andersen, M.N.; Rasmussen, T.A.; Søgaard, O.S.; Østergaard, L.; Denton, P.W.; Jakobsen, M.R. Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections. Antimicrob. Agents Chemother., 2015, 59(7), 3984-3994. [http://dx.doi.org/10.1128/AAC.00574-15]. [PMID: 25896701].
[77]
Stenzel, K.; Hamacher, A.; Hansen, F.K.; Gertzen, C.G.W.; Senger, J.; Marquardt, V.; Marek, L.; Marek, M.; Romier, C.; Remke, M.; Jung, M.; Gohlke, H.; Kassack, M.U.; Kurz, T. Alkoxyurea-based histone deacetylase inhibitors increase cisplatin potency in chemoresistant cancer cell lines. J. Med. Chem., 2017, 60(13), 5334-5348. [http://dx.doi.org/10.1021/acs.jmedchem.6b01538]. [PMID: 28581289].
[78]
Mitchell, A.E.; Zheng, J.; Hammock, B.D.; Lo Bello, M.; Jones, A.D. Structural and functional consequences of haloenol lactone inactivation of murine and human glutathione S-transferase. Biochemistry, 1998, 37(19), 6752-6759. [http://dx.doi.org/10.1021/bi971846r]. [PMID: 9578559].
[79]
Wu, Z.; Minhas, G.S.; Wen, D.; Jiang, H.; Chen, K.; Zimniak, P.; Zheng, J. Design, synthesis, and structure-activity relationships of haloenol lactones: site-directed and isozyme-selective glutathione S-transferase inhibitors. J. Med. Chem., 2004, 47(12), 3282-3294. [http://dx.doi.org/10.1021/jm0499615]. [PMID: 15163208].
[80]
Hood, K.; Shah, A. Belinostat for relapsed or refractory peripheral T-Cell lymphoma. J. Adv. Pract. Oncol., 2016, 7(2), 209-218. [PMID: 28090369].
[81]
Burgers, P.T.; Poolman, R.W.; Van Bakel, T.M.; Tuinebreijer, W.E.; Zielinski, S.M.; Bhandari, M.; Patka, P.; Van Lieshout, E.M. Reliability, validity, and responsiveness of the Western Ontario and McMaster Universities Osteoarthritis Index for elderly patients with a femoral neck fracture. J. Bone Joint Surg. Am., 2015, 97(9), 751-757. [http://dx.doi.org/10.2106/JBJS.N.00542]. [PMID: 25948522].
[82]
Qian, J.Z.G.; Qin, H.; Zhu, Y.; Xiao, Y. Method for synthesizing belinostat., China Patent 102786448 A, December 03. 2012.
[83]
Yang, L.X.X.Z.Y. Simple and Efficient Synthesis of Belinostat. Synth. Commun., 2010, 40, 2520-2540. [http://dx.doi.org/10.1080/00397910903277870].
[84]
Wang, Q.L. A process for preparing belinostat cis-isomer, China
Patent 105367455 A, October 24 2016.
[85]
Bao, X.S.D.; Qiao, X.; Zhao, X.; Chen, G. The Belinostat. Org. Process Res. Dev., 2016, 20(8), 1482-1488. [http://dx.doi.org/10.1021/acs.oprd.6b00170].
[86]
Savickiene, J.; Borutinskaite, V.V.; Treigyte, G.; Magnusson, K.E.; Navakauskiene, R. The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines. Eur. J. Pharmacol., 2006, 549(1-3), 9-18. [http://dx.doi.org/10.1016/j.ejphar.2006.08.010]. [PMID: 16978604].
[87]
Herman, D.; Jenssen, K.; Burnett, R.; Soragni, E.; Perlman, S.L.; Gottesfeld, J.M. Histone deacetylase inhibitors reverse gene silencing in Friedreich’s ataxia. Nat. Chem. Biol., 2006, 2(10), 551-558. [http://dx.doi.org/10.1038/nchembio815]. [PMID: 16921367].
[88]
Wang, H.; Guo, Y.; Fu, M.; Liang, X.; Zhang, X.; Wang, R.; Lin, C.; Qian, H. Antitumor activity of Chidamide in hepatocellular carcinoma cell lines. Mol. Med. Rep., 2012, 5(6), 1503-1508. [PMID: 22484326].
[89]
Gong, K.; Xie, J.; Yi, H.; Li, W. CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells. Biochem. J., 2012, 443(3), 735-746. [http://dx.doi.org/10.1042/BJ20111685]. [PMID: 22339555].
[90]
Yin, Z.; Wu, Z.; Lan, Y.L.C.; Shan, S. LI Z, Ning Z, Lu X, Li Z., Synthesis of chidamide,a new histone deacetylase (HDAC) inhibitor. Zhongguo Xin Yao Zazhi, 2004, 13(6), 536-538.
[91]
Todoerti, K.; Barbui, V.; Pedrini, O.; Lionetti, M.; Fossati, G.; Mascagni, P.; Rambaldi, A.; Neri, A.; Introna, M.; Lombardi, L.; Golay, J. Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. Haematologica, 2010, 95(2), 260-269. [http://dx.doi.org/10.3324/haematol.2009.012088]. [PMID: 19713220].
[92]
Bertolini, G.B.M.; Leoni, F.; Mizrahi, J.; Pavich, G.; Mascagni, P. Preparation of benzohydroxamic acids as antiinflammatory and immunosuppressive agents. PCT Int. Appl., 1997, 9743251, 20.
[93]
Wash, P.L.; Hoffman, T.Z.; Wiley, B.M.; Bonnefous, C.; Smith, N.D.; Sertic, M.S.; Lawrence, C.M.; Symons, K.T.; Nguyen, P.M.; Lustig, K.D.; Guo, X.; Annable, T.; Noble, S.A.; Hager, J.H.; Hassig, C.A.; Malecha, J.W. Alpha-mercaptoketone based histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(24), 6482-6485. [http://dx.doi.org/10.1016/j.bmcl.2008.10.058]. [PMID: 18954984].
[94]
Vanommeslaeghe, K.; Loverix, S.; Geerlings, P.; Tourwé, D. DFT-based ranking of zinc-binding groups in histone deacetylase inhibitors. Bioorg. Med. Chem., 2005, 13(21), 6070-6082. [http://dx.doi.org/10.1016/j.bmc.2005.06.009]. [PMID: 16006131].
[95]
Hassig, C.A.; Symons, K.T.; Guo, X.; Nguyen, P.M.; Annable, T.; Wash, P.L.; Payne, J.E.; Jenkins, D.A.; Bonnefous, C.; Trotter, C.; Wang, Y.; Anzola, J.V.; Milkova, E.L.; Hoffman, T.Z.; Dozier, S.J.; Wiley, B.M.; Saven, A.; Malecha, J.W.; Davis, R.L.; Muhammad, J.; Shiau, A.K.; Noble, S.A.; Rao, T.S.; Smith, N.D.; Hager, J.H. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo. Mol. Cancer Ther., 2008, 7(5), 1054-1065. [http://dx.doi.org/10.1158/1535-7163.MCT-07-2347]. [PMID: 18483295].
[96]
Payne, J.E.; Bonnefous, C.; Hassig, C.A.; Symons, K.T.; Guo, X.; Nguyen, P.M.; Annable, T.; Wash, P.L.; Hoffman, T.Z.; Rao, T.S.; Shiau, A.K.; Malecha, J.W.; Noble, S.A.; Hager, J.H.; Smith, N.D. Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitor. Bioorg. Med. Chem. Lett., 2008, 18(23), 6093-6096. [http://dx.doi.org/10.1016/j.bmcl.2008.10.029]. [PMID: 18954983].
[97]
Catley, L.; Weisberg, E.; Tai, Y.T.; Atadja, P.; Remiszewski, S.; Hideshima, T.; Mitsiades, N.; Shringarpure, R.; LeBlanc, R.; Chauhan, D.; Munshi, N.C.; Schlossman, R.; Richardson, P.; Griffin, J.; Anderson, K.C. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood, 2003, 102(7), 2615-2622. [http://dx.doi.org/10.1182/blood-2003-01-0233]. [PMID: 12816865].
[98]
Yeung, A.; Bhargava, R.K.; Ahn, R.; Bahna, S.; Kang, N.H.; Lacoul, A.; Niles, L.P. HDAC inhibitor M344 suppresses MCF-7 breast cancer cell proliferation. Biomed. Pharmacother., 2012, 66(3), 232-236. [http://dx.doi.org/10.1016/j.biopha.2011.06.007]. [PMID: 22436652].
[99]
Jung, M.; Brosch, G.; Kölle, D.; Scherf, H.; Gerhäuser, C.; Loidl, P. Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J. Med. Chem., 1999, 42(22), 4669-4679. [http://dx.doi.org/10.1021/jm991091h]. [PMID: 10579829].
[100]
Suzuki, T.; Nagano, Y.; Kouketsu, A.; Matsuura, A.; Maruyama, S.; Kurotaki, M.; Nakagawa, H.; Miyata, N. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J. Med. Chem., 2005, 48(4), 1019-1032. [http://dx.doi.org/10.1021/jm049207j]. [PMID: 15715470].
[101]
Martirosyan, A.; Leonard, S.; Shi, X.; Griffith, B.; Gannett, P.; Strobl, J. Actions of a histone deacetylase inhibitor NSC3852 (5-nitroso-8-quinolinol) link reactive oxygen species to cell differentiation and apoptosis in MCF-7 human mammary tumor cells. J. Pharmacol. Exp. Ther., 2006, 317(2), 546-552. [http://dx.doi.org/10.1124/jpet.105.096891]. [PMID: 16497787].
[102]
Zhou, W.; Tang, W.; Sun, Z.; Li, Y.; Dong, Y.; Pei, H.; Peng, Y.; Wang, J.; Shao, T.; Jiang, Z.; Yi, Z.; Chen, Y. Discovery and optimization of N-Substituted 2-(4-pyridinyl)thiazole carboxamides against tumor growth through regulating angiogenesis signaling pathways. Sci. Rep., 2016, 6, 33434. [http://dx.doi.org/10.1038/srep33434]. [PMID: 27633259].
[103]
Ibeanu, F.O.E.; Ibezim, A.; Okoro, U. Synthesis, characterization, computational and biological study of novel azabenzo [a]phenothiazine and azabenzo[b]phenoxazine heterocycles as potential antibiotic agent. Med. Chem. Res., 2018, 27, 1093-1102.
[104]
Strobl, J.S.; Seibert, C.W.; Li, Y.; Nagarkatti, R.; Mitchell, S.M.; Rosypal, A.C.; Rathore, D.; Lindsay, D.S. Inhibition of Toxo-plasma gondii and Plasmodium falciparum infections in vitro by NSC3852, a redox active antiproliferative and tumor cell differentiation agent. J. Parasitol., 2009, 95(1), 215-223. [http://dx.doi.org/10.1645/GE-1608.1]. [PMID: 18837587].
[105]
Scuto, A.; Kirschbaum, M.; Kowolik, C.; Kretzner, L.; Juhasz, A.; Atadja, P.; Pullarkat, V.; Bhatia, R.; Forman, S.; Yen, Y.; Jove, R. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood, 2008, 111(10), 5093-5100. [http://dx.doi.org/10.1182/blood-2007-10-117762]. [PMID: 18349321].
[106]
Siripragada, M.R.; Irfan, V.; Chirag, P.; Mayur, B.; Akash, J.; Ananda, B.T.; Pinky, P. Preparation of novel salts and polymorphic forms of Panobinostat., PCT Int. Appl., 2017221163, December 28. 2017.
[107]
Buggy, J.J.; Cao, Z.A.; Bass, K.E.; Verner, E.; Balasubramanian, S.; Liu, L.; Schultz, B.E.; Young, P.R.; Dalrymple, S.A. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol. Cancer Ther., 2006, 5(5), 1309-1317. [http://dx.doi.org/10.1158/1535-7163.MCT-05-0442]. [PMID: 16731764].
[108]
Bass, K.B., S.; Young, P. Heteroarylamides and related compounds and their preparation, pharmaceutical compositions, and a method of monitoring anti-tumor activity of an HDAC inhibitor., PCT Int.
Appl., 2006042035, May 26. 2006.
[109]
Wang, H.; Yu, N.; Chen, D.; Lee, K.C.; Lye, P.L.; Chang, J.W.; Deng, W.; Ng, M.C.; Lu, T.; Khoo, M.L.; Poulsen, A.; Sangthongpitag, K.; Wu, X.; Hu, C.; Goh, K.C.; Wang, X.; Fang, L.; Goh, K.L.; Khng, H.H.; Goh, S.K.; Yeo, P.; Liu, X.; Bonday, Z.; Wood, J.M.; Dymock, B.W.; Kantharaj, E.; Sun, E.T. Discovery of (2E)-3-2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile. J. Med. Chem., 2011, 54(13), 4694-4720. [http://dx.doi.org/10.1021/jm2003552]. [PMID: 21634430].
[110]
Mandl-Weber, S.; Meinel, F.G.; Jankowsky, R.; Oduncu, F.; Schmidmaier, R.; Baumann, P. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br. J. Haematol., 2010, 149(4), 518-528. [http://dx.doi.org/10.1111/j.1365-2141.2010.08124.x]. [PMID: 20201941].
[111]
Duan, W.; Li, J.; Inks, E.S.; Chou, C.J.; Jia, Y.; Chu, X.; Li, X.; Xu, W.; Zhang, Y. Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor. J. Med. Chem., 2015, 58(10), 4325-4338. [http://dx.doi.org/10.1021/acs.jmedchem.5b00317]. [PMID: 25906087].
[112]
Good, K.V.; Martínez de Paz, A.; Tyagi, M.; Cheema, M.S.; Thambirajah, A.A.; Gretzinger, T.L.; Stefanelli, G.; Chow, R.L.; Krupke, O.; Hendzel, M.; Missiaen, K.; Underhill, A.; Landsberger, N.; Ausió, J. Trichostatin A decreases the levels of MeCP2 expression and phosphorylation and increases its chromatin binding affinity. Epigenetics, 2017, 12(11), 934-944. [http://dx.doi.org/10.1080/15592294.2017.1380760]. [PMID: 29099289].
[113]
Hakami, N.Y.; Dusting, G.J.; Peshavariya, H.M.; Trichostatin, A. a histone deacetylase inhibitor suppresses NADPH Oxidase 4-derived redox signalling and angiogenesis. J. Cell. Mol. Med., 2016, 20(10), 1932-1944. [http://dx.doi.org/10.1111/jcmm.12885]. [PMID: 27297729].
[114]
Vigushin, D.M.; Ali, S.; Pace, P.E.; Mirsaidi, N.; Ito, K.; Adcock, I.; Coombes, R.C. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res., 2001, 7(4), 971-976. [PMID: 11309348].
[115]
Mori, K.K.K. Synthesis of trichostatin A, a potent differentiation inducer of Friend leukemic cells, and its antipode. Tetrahedron, 1988, 44(19), 6013-6020. [http://dx.doi.org/10.1016/S0040-4020(01)89789-1].
[116]
Zhang, S.D.W.; Wang, W. Efficient, enantioselective organocatalytic synthesis of trichostatin A. Adv. Synth. Catal., 2006, 348, 1228-1234. [http://dx.doi.org/10.1002/adsc.200606106].
[117]
Chatterjee, A.; Richer, J.; Hulett, T.; Iska, V.B.; Wiest, O.; Helquist, P. An efficient synthesis of (+/-)-trichostatic Acid and analogues: a new route to (+/-)-trichostatin A. Org. Lett., 2010, 12(4), 832-834. [http://dx.doi.org/10.1021/ol9029116]. [PMID: 20104892].
[118]
Cosner, C.C.; Helquist, P. Concise, convergent syntheses of (±)-trichostatin A utilizing a Pd-catalyzed ketone enolate α-alkeny-lation reaction. Org. Lett., 2011, 13(14), 3564-3567. [http://dx.doi.org/10.1021/ol200964m]. [PMID: 21688856].
[119]
Henning, S.W. 178 Preclinical characterization of 4SC-202, a novel isotype specific HDAC inhibitor. Eur. J. Cancer, Suppl., 2010, 8(7), 61. [http://dx.doi.org/10.1016/S1359-6349(10)71883-8].
[120]
Maier, T.B. N-Sulfonylpyrroles and their preparation, pharmaceutical
compositions, and use as histone deacetylase inhibitors. PCT
Int. Appl., 2006097474 2006.
[121]
Qian, C.; Lai, C.J.; Bao, R.; Wang, D.G.; Wang, J.; Xu, G.X.; Atoyan, R.; Qu, H.; Yin, L.; Samson, M.; Zifcak, B.; Ma, A.W.; DellaRocca, S.; Borek, M.; Zhai, H.X.; Cai, X.; Voi, M. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Clin. Cancer Res., 2012, 18(15), 4104-4113. [http://dx.doi.org/10.1158/1078-0432.CCR-12-0055]. [PMID: 22693356].
[122]
Bao, R. Treatment of cancers having K-Ras mutations.. PCT Int.
Appl., 2011032683 2011.
[123]
Hess-Stumpp, H. Histone deacetylase inhibitors and cancer: From cell biology to the clinic. Eur. J. Cell Biol., 2005, 84(2-3), 109-121. [http://dx.doi.org/10.1016/j.ejcb.2004.12.010]. [PMID: 15819394].
[124]
Trapani, D.; Esposito, A.; Criscitiello, C.; Mazzarella, L.; Locatelli, M.; Minchella, I.; Minucci, S.; Curigliano, G. Entinostat for the treatment of breast cancer. Expert Opin. Investig. Drugs, 2017, 26(8), 965-971. [http://dx.doi.org/10.1080/13543784.2017.1353077]. [PMID: 28718331].
[125]
Saito, A.; Yamashita, T.; Mariko, Y.; Nosaka, Y.; Tsuchiya, K.; Ando, T.; Suzuki, T.; Tsuruo, T.; Nakanishi, O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA, 1999, 96(8), 4592-4597. [http://dx.doi.org/10.1073/pnas.96.8.4592]. [PMID: 10200307].
[126]
Gediya, L.K.; Belosay, A.; Khandelwal, A.; Purushottamachar, P.; Njar, V.C. Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. Bioorg. Med. Chem., 2008, 16(6), 3352-3360. [http://dx.doi.org/10.1016/j.bmc.2007.12.007]. [PMID: 18166465].
[127]
Fournel, M.; Bonfils, C.; Hou, Y.; Yan, P.T.; Trachy-Bourget, M.C.; Kalita, A.; Liu, J.; Lu, A.H.; Zhou, N.Z.; Robert, M.F.; Gillespie, J.; Wang, J.J.; Ste-Croix, H.; Rahil, J.; Lefebvre, S.; Moradei, O.; Delorme, D.; Macleod, A.R.; Besterman, J.M.; Li, Z. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol. Cancer Ther., 2008, 7(4), 759-768. [http://dx.doi.org/10.1158/1535-7163.MCT-07-2026]. [PMID: 18413790].
[128]
Zhou, N.; Moradei, O.; Raeppel, S.; Leit, S.; Frechette, S.; Gaudette, F.; Paquin, I.; Bernstein, N.; Bouchain, G.; Vaisburg, A.; Jin, Z.; Gillespie, J.; Wang, J.; Fournel, M.; Yan, P.T.; Trachy-Bourget, M.C.; Kalita, A.; Lu, A.; Rahil, J.; MacLeod, A.R.; Li, Z.; Besterman, J.M.; Delorme, D. Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. J. Med. Chem., 2008, 51(14), 4072-4075. [http://dx.doi.org/10.1021/jm800251w]. [PMID: 18570366].
[129]
Butler, L.M.; Webb, Y.; Agus, D.B.; Higgins, B.; Tolentino, T.R.; Kutko, M.C.; LaQuaglia, M.P.; Drobnjak, M.; Cordon-Cardo, C.; Scher, H.I.; Breslow, R.; Richon, V.M.; Rifkind, R.A.; Marks, P.A. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin. Cancer Res., 2001, 7(4), 962-970. [PMID: 11309347].
[130]
Remiszewski, S.W.; Sambucetti, L.C.; Atadja, P.; Bair, K.W.; Cornell, W.D.; Green, M.A.; Howell, K.L.; Jung, M.; Kwon, P.; Trogani, N.; Walker, H. Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J. Med. Chem., 2002, 45(4), 753-757. [http://dx.doi.org/10.1021/jm015568c]. [PMID: 11831887].
[131]
Arts, J.; King, P.; Mariën, A.; Floren, W.; Beliën, A.; Janssen, L.; Pilatte, I.; Roux, B.; Decrane, L.; Gilissen, R.; Hickson, I.; Vreys, V.; Cox, E.; Bol, K.; Talloen, W.; Goris, I.; Andries, L.; Du Jardin, M.; Janicot, M.; Page, M.; van Emelen, K.; Angibaud, P. JNJ-26481585, a novel “second-generation” oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin. Cancer Res., 2009, 15(22), 6841-6851. [http://dx.doi.org/10.1158/1078-0432.CCR-09-0547]. [PMID: 19861438].
[132]
Dickens, J.H. Monohydrochloric salt of N-hydroxy-2-[4-([(1-
methyl-1H-indol-3-yl)methyl]aminomethyl)-1-piperidinyl]-5-
pyrimidinecarboxamide as HDAC inhibitors and its preparation,
pharmaceutical compositions and use in the treatment of cancer.
PCT Int. Appl., 2008138918 2008.
[133]
Soragni, E.; Miao, W.; Iudicello, M.; Jacoby, D.; De Mercanti, S.; Clerico, M.; Longo, F.; Piga, A.; Ku, S.; Campau, E.; Du, J.; Penalver, P.; Rai, M.; Madara, J.C.; Nazor, K.; O’Connor, M.; Maximov, A.; Loring, J.F.; Pandolfo, M.; Durelli, L.; Gottesfeld, J.M.; Rusche, J.R. Epigenetic therapy for Friedreich ataxia. Ann. Neurol., 2014, 76(4), 489-508. [http://dx.doi.org/10.1002/ana.24260]. [PMID: 25159818].
[134]
Sandi, C.; Pinto, R.M.; Al-Mahdawi, S.; Ezzatizadeh, V.; Barnes, G.; Jones, S.; Rusche, J.R.; Gottesfeld, J.M.; Pook, M.A. Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model. Neurobiol. Dis., 2011, 42(3), 496-505. [http://dx.doi.org/10.1016/j.nbd.2011.02.016]. [PMID: 21397024].
[135]
Rusche, J.P. Preparation of 6-aminohexanoic acid derivatives as
HDAC inhibitors. PCT Int. Appl., 2010028192, June 10 2014.
[136]
Sasakawa, Y.; Naoe, Y.; Inoue, T.; Sasakawa, T.; Matsuo, M.; Manda, T.; Mutoh, S. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem. Pharmacol., 2002, 64(7), 1079-1090. [http://dx.doi.org/10.1016/S0006-2952(02)01261-3]. [PMID: 12234611].
[137]
Blagosklonny, M.V.; Robey, R.; Sackett, D.L.; Du, L.; Traganos, F.; Darzynkiewicz, Z.; Fojo, T.; Bates, S.E. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol. Cancer Ther., 2002, 1(11), 937-941. [PMID: 12481415].
[138]
Kaneda, M.; Sueyoshi, K.; Teruya, T.; Ohno, H.; Fujii, N.; Oishi, S. Total synthesis of odoamide, a novel cyclic depsipeptide, from an Okinawan marine cyanobacterium. Org. Biomol. Chem., 2016, 14(38), 9093-9104. [http://dx.doi.org/10.1039/C6OB01583B]. [PMID: 27722687].
[139]
Greshock, T.J.; Johns, D.M.; Noguchi, Y.; Williams, R.M. Improved total synthesis of the potent HDAC inhibitor FK228 (FR-901228). Org. Lett., 2008, 10(4), 613-616. [http://dx.doi.org/10.1021/ol702957z]. [PMID: 18205373].
[140]
Wen, S.; Packham, G.; Ganesan, A. Macrolactamization versus macrolactonization: Total synthesis of FK228, the depsipeptide histone deacetylase inhibitor. J. Org. Chem., 2008, 73(23), 9353-9361. [http://dx.doi.org/10.1021/jo801866z]. [PMID: 18991384].
[141]
Jones, P.; Steinkühler, C. From natural products to small molecule ketone histone deacetylase inhibitors: Development of new class specific agents. Curr. Pharm. Des., 2008, 14(6), 545-561. [http://dx.doi.org/10.2174/138161208783885317]. [PMID: 18336299].
[142]
Su, G.H.; Sohn, T.A.; Ryu, B.; Kern, S.E. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res., 2000, 60(12), 3137-3142. [PMID: 10866300].
[143]
Sharma, V.; Koul, N.; Joseph, C.; Dixit, D.; Ghosh, S.; Sen, E. HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity. J. Cell. Mol. Med., 2010, 14(8), 2151-2161. [http://dx.doi.org/10.1111/j.1582-4934.2009.00844.x]. [PMID: 19583803].
[144]
Gerova, M.P.O. A Convenient Synthesis of the New Histone Deacetylase Inhibitor Scriptaid. Org. Prep. Proced. Int., 2014, 46, 76-79. [http://dx.doi.org/10.1080/00304948.2014.866471].
[145]
Fleming, C.L.; Ashton, T.D.; Nowell, C.; Devlin, M.; Natoli, A.; Schreuders, J.; Pfeffer, F.M. A fluorescent histone deacetylase (HDAC) inhibitor for cellular imaging. Chem. Commun. (Camb.), 2015, 51(37), 7827-7830. [http://dx.doi.org/10.1039/C5CC02059J]. [PMID: 25853994].
[146]
Graziano, M.J.; Spoon, T.A.; Cockrell, E.A.; Rowse, P.E.; Gonzales, A.J. Induction of apoptosis in rat peripheral blood lymphocytes by the anticancer drug CI-994 (Acetyldinaline)(*). J. Biomed. Biotechnol., 2001, 1(2), 52-61. [http://dx.doi.org/10.1155/S1110724301000146]. [PMID: 12488610].
[147]
Beckers, T.; Burkhardt, C.; Wieland, H.; Gimmnich, P.; Ciossek, T.; Maier, T.; Sanders, K. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int. J. Cancer, 2007, 121(5), 1138-1148. [http://dx.doi.org/10.1002/ijc.22751]. [PMID: 17455259].
[148]
Schölz, C.; Weinert, B.T.; Wagner, S.A.; Beli, P.; Miyake, Y.; Qi, J.; Jensen, L.J.; Streicher, W.; McCarthy, A.R.; Westwood, N.J.; Lain, S.; Cox, J.; Matthias, P.; Mann, M.; Bradner, J.E.; Choudhary, C. Acetylation site specificities of lysine deacetylase inhibitors in human cells. Nat. Biotechnol., 2015, 33(4), 415-423. [http://dx.doi.org/10.1038/nbt.3130]. [PMID: 25751058].
[149]
Wang, Y.; Stowe, R.L.; Pinello, C.E.; Tian, G.; Madoux, F.; Li, D.; Zhao, L.Y.; Li, J.L.; Wang, Y.; Wang, Y.; Ma, H.; Hodder, P.; Roush, W.R.; Liao, D. Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases. Chem. Biol., 2015, 22(2), 273-284. [http://dx.doi.org/10.1016/j.chembiol.2014.12.015]. [PMID: 25699604].
[150]
Liao, D.R., W.; Stowe, R. Benzohydrazides and related compounds
as HDAC inhibitors and their preparation and use for the treatment
of cell proliferation diseases., WO Patent 2015153516A1, October
08, 2015.
[151]
Chateauvieux, S.; Morceau, F.; Dicato, M.; Diederich, M. Molecular and therapeutic potential and toxicity of valproic acid. J. Biomed. Biotechnol., 2010, 2010479364 [doi: 10.1155/2010/479364].
[152]
F., C., Towards the rehabilitation of the Mathews’ ‘dry’ hydrolysis reaction using microwave technology. Tetrahedron Lett., 2002, 43, 5555-5557. [http://dx.doi.org/10.1016/S0040-4039(02)01127-9].
[153]
Palmieri, A.; Gabrielli, S.; Ballinia, R. Michael Reaction of Nitroalkanes with b-Nitroacrylates under a Solid Promoter: Advanced Regio- and Diastereoselective Synthesis of Nitro-Functionalized a,b-Unsaturated Esters and 1,3-Butadiene-2-carboxylates. Adv. Synth. Catal., 2010, 352, 1485-1492. [http://dx.doi.org/10.1002/adsc.201000142].
[154]
Salmi-Smail, C.; Fabre, A.; Dequiedt, F.; Restouin, A.; Castellano, R.; Garbit, S.; Roche, P.; Morelli, X.; Brunel, J.M.; Collette, Y. Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity. J. Med. Chem., 2010, 53(8), 3038-3047. [http://dx.doi.org/10.1021/jm901358y]. [PMID: 20218673].
[155]
Nebbioso, A.; Manzo, F.; Miceli, M.; Conte, M.; Manente, L.; Baldi, A.; De Luca, A.; Rotili, D.; Valente, S.; Mai, A.; Usiello, A.; Gronemeyer, H.; Altucci, L. Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep., 2009, 10(7), 776-782. [http://dx.doi.org/10.1038/embor.2009.88]. [PMID: 19498465].
[156]
Nebbioso, A.; Dell’Aversana, C.; Bugge, A.; Sarno, R.; Valente, S.; Rotili, D.; Manzo, F.; Teti, D.; Mandrup, S.; Ciana, P.; Maggi, A.; Mai, A.; Gronemeyer, H.; Altucci, L. HDACs class II-selective inhibition alters nuclear receptor-dependent differentiation. J. Mol. Endocrinol., 2010, 45(4), 219-228. [http://dx.doi.org/10.1677/JME-10-0043]. [PMID: 20639404].
[157]
Mai, A.; Massa, S.; Pezzi, R.; Simeoni, S.; Rotili, D.; Nebbioso, A.; Scognamiglio, A.; Altucci, L.; Loidl, P.; Brosch, G.; Class, I.I.; Class, I.I. IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J. Med. Chem., 2005, 48(9), 3344-3353. [http://dx.doi.org/10.1021/jm049002a]. [PMID: 15857140].
[158]
Fleming, C.L.; Ashton, T.D.; Gaur, V.; McGee, S.L.; Pfeffer, F.M. Improved synthesis and structural reassignment of MC1568: a class IIa selective HDAC inhibitor. J. Med. Chem., 2014, 57(3), 1132-1135. [http://dx.doi.org/10.1021/jm401945k]. [PMID: 24450497].
[159]
Darkin-Rattray, S.J.; Gurnett, A.M.; Myers, R.W.; Dulski, P.M.; Crumley, T.M.; Allocco, J.J.; Cannova, C.; Meinke, P.T.; Colletti, S.L.; Bednarek, M.A.; Singh, S.B.; Goetz, M.A.; Dombrowski, A.W.; Polishook, J.D.; Schmatz, D.M. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. USA, 1996, 93(23), 13143-13147. [http://dx.doi.org/10.1073/pnas.93.23.13143]. [PMID: 8917558].
[160]
Deshmukh, P.H.; Schulz‐Fademrecht, C.; Procopiou, P.A.; Vigushin, D.A.; Coombes, R.C.; Barretta, A.G.M. Ring-closing metathesis in the synthesis of biologically active peptidomimetics of Apicidin A. Adv. Synth. Catal., 2007, 349, 175-183. [http://dx.doi.org/10.1002/adsc.200600421].
[161]
Horne, W.S.; Olsen, C.A.; Beierle, J.M.; Montero, A.; Ghadiri, M.R. Probing the bioactive conformation of an archetypal natural product HDAC inhibitor with conformationally homogeneous triazole-modified cyclic tetrapeptides. Angew. Chem. Int. Ed. Engl., 2009, 48(26), 4718-4724. [http://dx.doi.org/10.1002/anie.200805900]. [PMID: 19267380].
[162]
Ralph, M. Inhibitors of histone deacetylase., PCT Int. Appl.,
2015069693, May 14. 2015.
[163]
Wood, T.E.; Dalili, S.; Simpson, C.D.; Sukhai, M.A.; Hurren, R.; Anyiwe, K.; Mao, X.; Suarez Saiz, F.; Gronda, M.; Eberhard, Y.; MacLean, N.; Ketela, T.; Reed, J.C.; Moffat, J.; Minden, M.D.; Batey, R.A.; Schimmer, A.D. Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol. Cancer Ther., 2010, 9(1), 246-256. [http://dx.doi.org/10.1158/1535-7163.MCT-09-0495]. [PMID: 20053768].
[164]
Malvaez, M.; McQuown, S.C.; Rogge, G.A.; Astarabadi, M.; Jacques, V.; Carreiro, S.; Rusche, J.R.; Wood, M.A. HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc. Natl. Acad. Sci. USA, 2013, 110(7), 2647-2652. [http://dx.doi.org/10.1073/pnas.1213364110]. [PMID: 23297220].
[165]
Vincent, J.; James, R.; Jasbir, S.; Norton, P. Preparation of N-(2-
aminophenyl) heteroarylacrylamides as histone deacetylase inhibitors.
PCT Int. Appl., 2012118782, September 07 2012.
[166]
Chung, Y.M.; Wei, C.K.; Chuang, D.W.; El-Shazly, M.; Hsieh, C.T.; Asai, T.; Oshima, Y.; Hsieh, T.J.; Hwang, T.L.; Wu, Y.C.; Chang, F.R. An epigenetic modifier enhances the production of anti-diabetic and anti-inflammatory sesquiterpenoids from Aspergillus sydowii. Bioorg. Med. Chem., 2013, 21(13), 3866-3872. [http://dx.doi.org/10.1016/j.bmc.2013.04.004]. [PMID: 23647825].
[167]
Balasubramanian, S.; Ramos, J.; Luo, W.; Sirisawad, M.; Verner, E.; Buggy, J.J. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia, 2008, 22(5), 1026-1034. [http://dx.doi.org/10.1038/leu.2008.9]. [PMID: 18256683].
[168]
Olson, D.E.; Udeshi, N.D.; Wolfson, N.A.; Pitcairn, C.A.; Sullivan, E.D.; Jaffe, J.D.; Svinkina, T.; Natoli, T.; Lu, X.; Paulk, J.; McCarren, P.; Wagner, F.F.; Barker, D.; Howe, E.; Lazzaro, F.; Gale, J.P.; Zhang, Y.L.; Subramanian, A.; Fierke, C.A.; Carr, S.A.; Holson, E.B. An unbiased approach to identify endogenous substrates of “histone” deacetylase 8. ACS Chem. Biol., 2014, 9(10), 2210-2216. [http://dx.doi.org/10.1021/cb500492r]. [PMID: 25089360].
[169]
Pavlik, C.M.; Wong, C.Y.; Ononye, S.; Lopez, D.D.; Engene, N.; McPhail, K.L.; Gerwick, W.H.; Balunas, M.J.; Santacruzamate, A. Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp. J. Nat. Prod., 2013, 76(11), 2026-2033. [http://dx.doi.org/10.1021/np400198r]. [PMID: 24164245].
[170]
Marek, L.; Hamacher, A.; Hansen, F.K.; Kuna, K.; Gohlke, H.; Kassack, M.U.; Kurz, T. Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. J. Med. Chem., 2013, 56(2), 427-436. [http://dx.doi.org/10.1021/jm301254q]. [PMID: 23252603].
[171]
Lobera, M.; Madauss, K.P.; Pohlhaus, D.T.; Wright, Q.G.; Trocha, M.; Schmidt, D.R.; Baloglu, E.; Trump, R.P.; Head, M.S.; Hofmann, G.A.; Murray-Thompson, M.; Schwartz, B.; Chakravorty, S.; Wu, Z.; Mander, P.K.; Kruidenier, L.; Reid, R.A.; Burkhart, W.; Turunen, B.J.; Rong, J.X.; Wagner, C.; Moyer, M.B.; Wells, C.; Hong, X.; Moore, J.T.; Williams, J.D.; Soler, D.; Ghosh, S.; Nolan, M.A. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat. Chem. Biol., 2013, 9(5), 319-325. [http://dx.doi.org/10.1038/nchembio.1223]. [PMID: 23524983].
[172]
Baloglu, E.; Ghosh, S.; Lobera, M.; Schmidt, D. Preparation of five
membered heterocycle-containing benzamide and nicotinamide
compounds as inhibitors of histone deacetylase (HDAC) enzymes.
PCT Int. Appl., 2011088181 2011.
[173]
Olsson, A.; Björk, A.; Vallon-Christersson, J.; Isaacs, J.T.; Leanderson, T. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol. Cancer, 2010, 9, 107. [http://dx.doi.org/10.1186/1476-4598-9-107]. [PMID: 20470445].
[174]
Guerriero, J.L.; Sotayo, A.; Ponichtera, H.E.; Castrillon, J.A.; Pourzia, A.L.; Schad, S.; Johnson, S.F.; Carrasco, R.D.; Lazo, S.; Bronson, R.T.; Davis, S.P.; Lobera, M.; Nolan, M.A.; Letai, A. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature, 2017, 543(7645), 428-432. [http://dx.doi.org/10.1038/nature21409]. [PMID: 28273064].
[175]
Butler, K.V.; Kalin, J.; Brochier, C.; Vistoli, G.; Langley, B.; Kozikowski, A.P. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J. Am. Chem. Soc., 2010, 132(31), 10842-10846. [http://dx.doi.org/10.1021/ja102758v]. [PMID: 20614936].
[176]
Hong, J.X.X.; Das, D.; Yang, P.Y.; Chen, S.H.; Li, G. A New Approach to Tubacin. Lett. Org. Chem., 2010, 7, 50-53. [http://dx.doi.org/10.2174/157017810790533913].
[177]
Steven, Q; Teru, H; Kenneth, C A Pharmaceutical combinations
comprising a histone deacetylase inhibitor and a programmed
death-ligand 1 (PD-L1) inhibitor and methods of use thereof. PCT
Int. Appl., 2018098168 2018.
[178]
Jochems, J.; Boulden, J.; Lee, B.G.; Blendy, J.A.; Jarpe, M.; Mazitschek, R.; Van Duzer, J.H.; Jones, S.; Berton, O. Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability. Neuropsychopharmacology, 2014, 39(2), 389-400. [http://dx.doi.org/10.1038/npp.2013.207]. [PMID: 23954848].
[179]
Simon, J.S.; Eva, S.; Pinilla, I.J.; Simon, J.S.S.Q.N.; Eva, S.; Pinilla, I.J. HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia., PCT Int.
Appl., 2017184774. 2017.
[180]
Yu, J.; Ma, M.; Ma, Z.; Fu, J. HDAC6 inhibition prevents TNF-α-induced caspase 3 activation in lung endothelial cell and maintains cell-cell junctions. Oncotarget, 2016, 7(34), 54714-54722. [http://dx.doi.org/10.18632/oncotarget.10591]. [PMID: 27419634].
[181]
Kozikowski, A.P.; Tapadar, S.; Luchini, D.N.; Kim, K.H.; Billadeau, D.D. Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J. Med. Chem., 2008, 51(15), 4370-4373. [http://dx.doi.org/10.1021/jm8002894]. [PMID: 18642892].
[182]
Lee, J.H.; Mahendran, A.; Yao, Y.; Ngo, L.; Venta-Perez, G.; Choy, M.L.; Kim, N.; Ham, W.S.; Breslow, R.; Marks, P.A. Development of a histone deacetylase 6 inhibitor and its biological effects. Proc. Natl. Acad. Sci. USA, 2013, 110(39), 15704-15709. [http://dx.doi.org/10.1073/pnas.1313893110]. [PMID: 24023063].
[183]
Bergman, J.A.; Woan, K.; Perez-Villarroel, P.; Villagra, A.; Sotomayor, E.M.; Kozikowski, A.P. Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J. Med. Chem., 2012, 55(22), 9891-9899. [http://dx.doi.org/10.1021/jm301098e]. [PMID: 23009203].
[184]
Suzuki, T.; Kouketsu, A.; Itoh, Y.; Hisakawa, S.; Maeda, S.; Yoshida, M.; Nakagawa, H.; Miyata, N. Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. J. Med. Chem., 2006, 49(16), 4809-4812. [http://dx.doi.org/10.1021/jm060554y]. [PMID: 16884291].
[185]
Itoh, Y.; Suzuki, T.; Kouketsu, A.; Suzuki, N.; Maeda, S.; Yoshida, M.; Nakagawa, H.; Miyata, N. Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. J. Med. Chem., 2007, 50(22), 5425-5438. [http://dx.doi.org/10.1021/jm7009217]. [PMID: 17929798].
[186]
Kozlov, M.V.A.; Konduktorov, K.A.; Kochetkov, S.N. A new synthesis of 6-N-hydroxy-4-(2-methyl-1,2,3,4-tetrahydro-pyrido-[4,3-b]indol-5-ylmethyl)benzamide, tubastatin a, a highly selective inhibitor of histone deacetylase. Russ. J. Bioorganic Chem., 2013, 39(1), 102-105. [http://dx.doi.org/10.1134/S1068162012060076].
[187]
Bots, M.; Johnstone, R.W. Rational combinations using HDAC inhibitors. Clin. Cancer Res., 2009, 15(12), 3970-3977. [http://dx.doi.org/10.1158/1078-0432.CCR-08-2786]. [PMID: 19509171].
[188]
Ali, M.; Hom, R.A.; Blakeslee, W.; Ikenouye, L.; Kutateladze, T.G. Diverse functions of PHD fingers of the MLL/KMT2 subfamily. Biochim. Biophys. Acta, 2014, 1843(2), 366-371. [http://dx.doi.org/10.1016/j.bbamcr.2013.11.016]. [PMID: 24291127].
[189]
Arrowsmith, C.H.; Bountra, C.; Fish, P.V.; Lee, K.; Schapira, M. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov., 2012, 11(5), 384-400. [http://dx.doi.org/10.1038/nrd3674]. [PMID: 22498752].
[190]
Kalakonda, N.; Fischle, W.; Boccuni, P.; Gurvich, N.; Hoya-Arias, R.; Zhao, X.; Miyata, Y.; Macgrogan, D.; Zhang, J.; Sims, J.K.; Rice, J.C.; Nimer, S.D. Histone H4 lysine 20 monomethylation promotes transcriptional repression by L3MBTL1. Oncogene, 2008, 27(31), 4293-4304. [http://dx.doi.org/10.1038/onc.2008.67]. [PMID: 18408754].
